

Index

A

- Accommodation
 - induction, 248
 - mouse models, 114–115
- Acute rejection
 - B-cell role, 56–58
 - biomarkers, 46–49
 - chemokines, 43–45, 52
 - innate immunity, 52–54, 245–247
 - kidney transplantation, 344–346
 - mouse models
 - antibody-mediated rejection, 112–113
 - heart transplantation, 109–110
 - kidney transplantation, 110–111
 - skin transplantation, 108–109
 - overview, 41–42
 - T-cell role
 - activation, 54–56
 - memory T cells, 56
 - regulatory T cells, 55
- AEB-071. *See* Sotrastaurin
- Alefacept, immunosuppression therapy, 102
- Alemtuzumab
 - immunosuppression induction, 96–97
 - lymphocyte depletion, 146
- Allogeneic response. *See also* Rejection
 - allogeneic nonself, 30
 - B cell, 35, 37
 - graft endothelium role, 36–37, 54
 - innate immune cells, 32–33, 35–36
 - overview, 29–30
 - prospects for study, 37
 - T cell
 - alloreactivity, 30–32
 - T-cell receptor gene rearrangement, 31
 - types in transplanted organ recognition, 34–35
- All-*trans* retinoic acid (ATRA), regulatory T-cell stability effects, 194
- ALS. *See* Antilymphocyte serum
- AMR. *See* Antibody-mediated rejection
- Antibody-mediated rejection (AMR)
 - acute humoral response, 57–58
 - complement role, 81–82
 - epitopes, 241–243
 - heart transplantation, 321–322
 - kidney transplantation, 345–346
 - macrophage role, 53–54

- mechanisms, 240–243
- mouse models
 - acute rejection, 112–113
 - chronic rejection, 113–114
 - hyperacute rejection, 112
- prevention
 - accommodation induction, 248
 - antibody or antibody-producing cell removal, 248
 - antigen removal, 247
 - B-cell tolerance induction, 248
 - complement cascade prevention, 247–248
- Antilymphocyte serum (ALS), history of use, 13
- Antithymocyte globulin (ATG)
 - immunosuppression induction, 95–96
 - primate model use, 132–133, 145
- ATG. *See* Antithymocyte globulin
- ATRA. *See* All-*trans* retinoic acid
- Azathioprine
 - immunosuppression maintenance, 97
 - primate model use, 128

B

- B cell. *See also* Antibody-mediated rejection;
Lymphocyte depletion
 - acute rejection role, 56–58
 - allogeneic response, 35, 37
 - allograft rejection role, 43
 - mesenchymal stromal cell interactions with allogeneic cells, 231–232
 - tolerance induction, 248
- Basiliximab, immunosuppression induction, 96
- β-Cell transplantation. *See* Islet transplantation;
Pancreas transplantation
- Betacept, immunosuppression maintenance, 99–100
- Billingham, Rupert, 6–8, 259
- Bioethics. *See* Ethics, transplantation
- BK virus, kidney transplantation infection, 349–350
- Bortezomib, immunosuppression therapy, 101

C

- Calne, Roy, 9–10
- Campath-1H. *See* Alemtuzumab
- CAN. *See* Chronic allograft nephropathy

- Cancer. *See also* Posttransplantation lymphoproliferative disease
guidelines for transplantation by cancer type, 386
kidney transplant patient management, 394–395
preexisting cancer
deceased donors, 385, 387–388
organ donors, 384–385
transplant recipients, 381–382
risk
classification, 387
immunosuppression regimens, 391–392
organ transplantation and cancer types, 389–390
screening in transplant recipients
breast cancer, 393
cervical cancer, 393
colon cancer, 394
renal cancer, 394
skin cancer, 394
survival in transplant recipients, 392–393
transmission by type, 387
viral infection in carcinogenesis after transplantation, 390–391
- Carrel, Alexis, 2–4, 407–408
- CCR2, allograft rejection role, 45
- CCR4, allograft rejection role, 45
- CCR5, allograft rejection role, 43–44
- CCR7, allograft rejection role, 45
- CD3 immunotoxin, lymphocyte depletion, 135, 147
- CD28, costimulatory blockade, 130, 177–179, 184–185, 265
- CD40, costimulatory blockade, 180–181, 185, 249, 265–266
- CD40 L. *See* CD154
- CD58. *See* LFA-3
- CD134. *See* OX40
- CD137. *See* 4-1BB
- CD154 (CD40 L), costimulatory blockade, 131, 180–183, 185, 249, 265–266
- Chimerism, tolerance induction
clinical studies of mixed chimerism, 164–166, 252–263
history of study, 14–16
mechanism of mixed chimerism induction, 166–169
mouse model studies
lymphocyte depletion, 158–159
mixed chimerism, 160
pig studies of mixed chimerism, 164–166, 252–263
primate models
central tolerance with mixed chimerism, 115–116, 163–164
peripheral tolerance with costimulatory blockade, 116
prospects for study, 169–170
- Chronic allograft nephropathy (CAN), 58–59
- Chronic lung allograft dysfunction (CLAD), 313–314
- Chronic rejection
antibodies, 60–61
antibody-mediated rejection mouse models, 113–114
biomarkers, 49–50
endothelial cell role, 60–61
fibrosis, 61–62
histological lesions, 59–60
human leukocyte antigen antibodies, 61
mechanisms, 58–59
overview, 42
- CLAD. *See* Chronic lung allograft dysfunction
- CMV. *See* Cytomegalovirus
- Complement
antibody-mediated rejection role, 81–82
antibody-mediated rejection therapeutic targeting, 247–248
C3 activation, 76–77
cascade, 78
cell-mediated graft rejection role, 80–81
inflammatory injury mediation shortly after transplantation, 77, 79–80
ischemia–reperfusion injury role, 77, 79, 87
mesenchymal stromal cell response, 227
Toll-like receptor pathway cross talk, 86
- Costimulatory blockade. *See also specific molecules*
clinical studies
CD154 antibody, 183
CTLA-4 antibody, 183–184
off-target effects, 267
peripheral tolerance induction, 116
primate models
CD154 antibody, 182–183
CTLA-4 antibody, 130–131, 182
prospects
activation of inhibitors, 185
CD154/CD40, 185
CD28 blockade, 184–185
LFA-3, 185–186
systemic immunosuppression, 249
targets
CD28/CTLA-4, 177–179
CD40/CD154, 180–181, 265–266
inducible T-cell costimulator, 179–180
OX40, 181/4-1BB, 181–182
programmed death 1 receptor, 180
transgenic animal studies, 249
- CP-690550. *See* Tofacitinib
- CRM9, lymphocyte depletion, 147
- CsA. *See* Cyclosporine
- CTLA-4
costimulatory blockade
activation of inhibitors, 185
clinical studies, 183–184
overview, 177–179, 265
peripheral tolerance induction, 116–117
primate model studies, 130–131, 182
regulatory T-cell function, 196

- CXCR3, allograft rejection role, 44–45
Cyclosporine (CsA)
 history of use, 13–14
 immunosuppression maintenance, 98
 primate model use, 129
Cytomegalovirus (CMV)
 lymphocyte depletion association, 149
 opportunistic infection, 372, 377–380
 prophylaxis, 378
- D**
Daclizumab, immunosuppression induction, 96
DC. *See* Dendritic cell
Delayed graft function (DGF), kidney, 343–344
Dempster, William, 4–5
Dendritic cell (DC)
 acute rejection role, 54
 allogeneic response, 33, 35–36
 allograft rejection role, 42–43
 mesenchymal stromal cell modulation,
 229–230
 plasmacytoid dendritic cell hypothesis of tolerance
 induction
 kidney transplantation, 325
 liver transplantation, 326
DGF. *See* Delayed graft function
Diabetes. *See also* Islet transplantation; Pancreas
 transplantation
 complications, 289–293
 islet transplantation, 25
 kidney transplantation, 23–24
 renal failure progression, 289
Donald, Hugh, 6
- E**
EBV. *See* Epstein–Barr virus
Eculizumab, immunosuppression therapy, 101
Endothelial cell
 acute rejection role, 54
 allograft rejection role, 36–37
 chronic rejection role, 60–61
 growth factor receptors in activation, 61
Epstein–Barr virus (EBV). *See also*
 Posttransplantation
 lymphoproliferative disease
 opportunistic infection, 372, 375, 377–379
Ethics, transplantation
 default to donation policy, 401–402
 encouraged volunteerism
 enforcement, 402
 inadequacy in organ donation, 400
 markets for organs, 400–401
 organ procurement policy, 399–400
 organ rationing and justice, 404–405
 recipient equity and organ distribution fairness,
 402–404
Everolimus, immunosuppression maintenance, 99
- F**
Facial transplantation
 complications, 364–366
 immunosuppression, 363–364
 outcomes
 motor function, 359–362
 nerve sensitivity, 359
 patient satisfaction, 363
 peripheral nerve regeneration and cortical
 integration, 360, 363
 overview, 355–356
 primate models, 128
 prospects, 366
 rejection, 364
 surgical technique, 356–358
Fibrosis, chronic rejection, 61–62
Fingolimod (FTY720), primate model use, 130, 146
4-1BB (CD137), costimulatory blockade, 181–182
Foxp3, regulatory T-cell induction, 192–193
FTY720. *See* Fingolimod
- G**
GATA3, 199
Gibson, Thomas, 5–6
Glucocorticoids, immunosuppression maintenance,
 97–98
Graft-versus-host disease (GVHD)
 chimerism studies, 133–134
 hematopoietic cell transplantation, 158, 266–267
 history of study, 8
 mixed chimerism studies in mice, 160
Guthrie, Charles, 3
GVHD. *See* Graft-versus-host disease
- H**
Hamburger, Jean, 8–9
Hand transplantation
 complications, 364–366
 immunosuppression, 363–364
 outcomes
 motor function, 359–362
 nerve sensitivity, 359
 patient satisfaction, 363
 peripheral nerve regeneration and cortical
 integration, 360, 363
 overview, 355–356
 primate models, 128–129
 prospects, 366
 rejection, 364
 surgical technique, 356–358

- HAR. *See* Hyperacute rejection
- Heart transplantation
- antibody-mediated rejection, 321–322
 - heart/kidney transplantation outcomes, 329–335
 - heart/lung transplantation, 312
 - immunosuppression, 320–321
 - kidney-induced cardiac allograft induction
 - overview, 327
 - primate models, 329
 - regulatory T-cell studies
 - coculture suppression assays, 328–329
 - host thymectomy, 328
 - major histocompatibility complex-mismatched swine, 329
 - putative intragraft Tregs, 329
 - roles
 - donor antigen load, 327–328
 - donor kidney irradiation, 328
 - donor nephrectomy, 328
 - mouse models of acute rejection, 109–110
 - organ preservation, 322
 - outcomes, 322
 - overview, 25, 319–320
 - primate models, 128
 - recipient demographics, 320
 - surgical technique, 322
- Hepatitis, opportunistic infection, 372–374, 378–379
- Herpes simplex virus (HSV), opportunistic infection, 372–373, 377
- HHV-8. *See* Human herpes virus 8
- Histocompatibility typing, historical perspective, 12–13
- Historical perspective, transplantation
- brain death in donors, 11
 - chimerism, 14–16
 - early history, 1–2
 - hemolysis for renal failure, 11
 - histocompatibility typing, 12–13
 - immunosuppression, 9–10, 13–14
 - kidney transplantation, 4–5, 8, 11–13
 - liver transplantation, 275–276
 - lung transplantation, 305–306
 - National Research Council conference of 1963, 19–20
 - organ preservation, 11
 - organ sharing, 12
 - pioneers, 2–4
 - skin transplantation, 5–8
- HIV. *See* Human immunodeficiency virus
- HPV. *See* Human papillomavirus
- HSV. *See* Herpes simplex virus
- HTLV. *See* Human T-cell lymphotropic virus
- Human herpes virus 8 (HHV8), infection in
- carcinogenesis after transplantation, 391
- Human immunodeficiency virus (HIV), transplant recipients, 372–373
- Human leukocyte antigen. *See* Major histocompatibility complex, 61
- Human papillomavirus (HPV), infection in
- carcinogenesis after transplantation, 391
- Human T-cell lymphotropic virus (HTLV), transplant recipient infection, 372–373
- Hume, David, 5
- Hunter, John, 6
- Hyperacute rejection (HAR)
- antibody-mediated rejection mouse models, 112
 - overview, 41, 240–243
- I**
- ICOS. *See* Inducible T-cell costimulator
- IL-2. *See* Interleukin-2
- IL-10. *See* Interleukin-10
- IL-35. *See* Interleukin-35
- Immune reconstitution syndrome (IRIS), 380
- Immunosuppression. *See also* Costimulatory blockade; Opportunistic infection; *specific drugs*
- cancer risks, 391–392
 - drug types
 - agents against B cells, plasma cells, and complement, 100–101
 - induction agents, 95–97
 - maintenance agents, 95, 97–100
 - novel drugs, 102–103
 - overview, 94–95
 - facial and hand transplantation, 363–364
 - heart transplantation, 320–321
 - historical perspective, 9–10, 13–14
 - lung transplantation, 313
 - mechanisms of action, 92–94
 - overview, 91
 - pancreas transplantation, 299
 - primate models
 - adhesion blockade, 132
 - lymphocyte depletion, 132–133
 - standard immunosuppression, 128–130
 - regenerative medicine and avoidance, 412–414
 - regulatory T-cell effects and adjunct therapy, 213–214
 - weaning for tolerance, 262
- Inducible T-cell costimulator (ICOS), costimulatory blockade, 179–180
- Infection. *See* Opportunistic infection
- Interferon- γ (IFN- γ), acute rejection role, 52, 54
- Interleukin-2 (IL-2)
- receptor antagonists, 96
 - regulatory T-cell function and effects, 195, 264
- Interleukin-10 (IL-10), regulatory T-cell function, 196
- Interleukin-35 (IL-35), regulatory T-cell function, 196
- Intravenous immunoglobulin (IVIg), immunosuppression therapy, 100–101

Index

- IRF4, 199
IRIS. *See* Immune reconstitution syndrome
ISA247. *See* Voclosporin
Ischemia–reperfusion injury
 complement role, 77, 79
 mesenchymal stromal cell role, 227–228
 T-cell facilitation
 Toll-like receptor role, 82–84
Islet transplantation
 benefits, 293
 cell isolation and implantation, 298–299
 challenges, 300–301
 complement interference, 79–80
 diabetes, 25
 encapsulation in immune response avoidance, 249
 immunosuppression, 299
 living donation, 298
 monitoring of graft, 299–300
 morbidity, 300
 outcomes, 293–295, 297
 primate models, 127–128
IVIG. *See* Intravenous immunoglobulin
- J**
- JAK. *See* Janus kinase
Janus kinase (JAK), inhibition of JAK3 for
 immunosuppression, 102, 130
Jensen, Carl, 2
- K**
- KICAT. *See* Kidney-induced cardiac allograft induction
Kidney-induced cardiac allograft induction (KICAT)
 heart/kidney transplantation outcomes in humans,
 329–335
 overview, 327
 primate models, 329
 regulatory T-cell studies
 coculture suppression assays, 328–329
 host thymectomy, 328
 major histocompatibility complex-mismatched
 swine, 329
 putative intragraft Tregs, 329
 roles
 donor antigen load, 327–328
 donor kidney irradiation, 328
 donor nephrectomy, 328
 survival rates, 409
 waiting list, 410–412
Kidney transplantation
 cancer management, 394–395
 cancer risks, 385
 complications
 early
 acute rejection, 344–346
 antibody-mediated rejection, 345–346
 delayed graft function, 343–344
 T-cell-mediated rejection, 345
 thrombotic microangiopathy, 347
 ureteral obstruction, 343
 urinary retention, 342
 urine leak, 342–343
 first year
 BK virus infection, 349–350
 recurrent kidney disease, 347–349
 late allograft failure, 350–352
 diabetes, 23–24
 elderly, 23
 heart/kidney transplantation outcomes, 329–335
 historical perspective, 4–5, 8, 11–13
 living donor assessment, 388
 mortality causes, 260
 mouse models of acute rejection, 110–111
 overview, 20–22, 341
 preemptive transplantation, 22–23
 pregnancy considerations, 352–353
 primate models, 126, 322
 quality of life, 25–26
 tolerance induction in mice
 alloimmune response, 324–325
 plasmacytoid dendritic cell hypothesis, 325
 renal tubular epithelial cell hypothesis, 325
- L**
- LAS. *See* Lung Allocation Score
Lawler, Richard, 5
Leflunomide, immunosuppression maintenance, 100
LFA-1, adhesion blockade, 132, 266
LFA-3 (CD58), adhesion blockade, 132, 185–186
Lillie, Frank, 7
Liver transplantation
 contraindications, 277–278
 deceased-donor liver transplantation, 280–281
 historical perspective, 275–276
 indications, 276–277
 listing of patients, 280
 living-donor liver transplantation, 281–282
 lymphocyte depletion, 149
 overview, 25
 patient evaluation, 278–280
 posttransplant care, 283–284
 prospects, 284–285
 surgical techniques, 282–283
 timing and allocation, 280
 tolerance induction in mice
 alloimmune response, 325–326
 hematopoietic stem cell hypothesis, 326
 liver sinusoidal endothelial cell hypothesis, 326
 plasmacytoid dendritic cell hypothesis, 326
Loeb, Leo, 4
Lung Allocation Score (LAS), 26

Index

- Lung transplantation
bridge therapy, 307–308
chronic lung allograft dysfunction, 313–314
contraindications, 307
donors
donation after cardiac death, 309–310
lung allocation, 26, 307
lung evaluation, 310
lung injury considerations, 309
selection, 308–309
heart/lung transplantation, 312
historical perspective, 305–306
immunosuppression, 313
indications, 306
organ preservation, 310–311
outcomes, 313
overview, 26
pediatrics, 307
postoperative care, 312–313
primate models, 128
prospects, 314–315
surgical technique, 312
unilateral versus bilateral, 311
volume reduction, 311–312
- Lymphocyte depletion
clinical studies, 147–149
complications
infection, 149–150
posttransplantation lymphoproliferative disease, 148, 150
mouse models
B-cell depletion, 143–144
natural killer cell depletion, 144
plasma cell depletion, 144
T-cell depletion, 142–143
overview, 141–142
pig studies, 161–162
primate models
B-cell depletion, 146–147
overview, 132–133
T-cell depletion
alemtuzumab, 146
CD3 immunotoxin, 135
miscellaneous agents, 146
polyclonal antibody preparations, 144–145
prospects for study, 151
repopulation of cells, 150–151
- M**
- Macrophage
acute rejection role, 52–53, 245–247
antibody-mediated rejection role, 53–54
mesenchymal stromal cell modulation, 228–229
therapeutic manipulation, 266
- Major histocompatibility complex (MHC)
allogeneic response, 30–31
antibodies in chronic rejection, 61
endothelial cells, 54
histocompatibility typing historical perspective, 12–13
monkeys, 125–126
- Mammalian target of rapamycin (mTOR)
inhibitors and cancer risks, 392, 395
regulatory T-cell regulation, 198
- MCP-1. *See* Monocyte chemoattractant protein-1
- Medawar, Peter, 4–8
- MEDI-507. *See* Siplizumab
- 6-Mercaptopurine, history of use, 9–10
- Mesenchymal stromal cell (MSC)
B-cell interactions, 231–232
functional overview, 225–226
immunogenicity of allogeneic cells, 232–233
ischemia–reperfusion injury role, 227–228
prospects for study, 234
therapeutic application, 233–234
tolerance studies
dendritic cell modulation by mesenchymal stromal cells, 229–230
macrophage modulation by mesenchymal stromal cells, 228–229
suppression of allogeneic T-cell responses in rejection, 230–231
- MHC. *See* Major histocompatibility complex
- Mixed chimerism. *See* Chimerism
- MMF. *See* Mycophenolate mofetil
- Monocyte chemoattractant protein-1 (MCP-1), therapeutic targeting, 52–53
- Mouse models, transplantation
acute rejection
heart transplantation, 109–110
kidney transplantation, 110–111
skin transplantation, 108–109
antibody-independent roles for T cells in transplantation, 114
antibody-mediated rejection
acute rejection, 112–113
chronic rejection, 113–114
hyperacute rejection, 112
graft accommodation, 114–115
limitations, 124
lymphocyte depletion
B-cell depletion, 143–144
natural killer cell depletion, 144
plasma cell depletion, 144
T-cell depletion, 142–143
prospects, 113
rejection and organ-specific differences, 323
spontaneous transplant models, 112–113
tolerance induction, organ-specific differences
kidney allografts

- alloimmune response, 324–325
 - plasmacytoid dendritic cell hypothesis, 325
 - renal tubular epithelial cell hypothesis, 325
 - liver allografts
 - alloimmune response, 325–326
 - hematopoietic stem cell hypothesis, 326
 - liver sinusoidal endothelial cell
 - hypothesis, 326
 - plasmacytoid dendritic cell hypothesis, 326
 - overview, 323–324
 - tolerance induction studies
 - central tolerance with mixed chimerism, 115–116
 - lymphocyte depletion, 158–159
 - mixed chimerism, 160
 - peripheral tolerance with costimulatory blockade, 116
 - MSC. *See* Mesenchymal stromal cell
 - mTOR. *See* Mammalian target of rapamycin
 - Muromonab
 - immunosuppression induction, 97
 - safety, 149–150
 - Murphy, James B., 2–3
 - Murray, Joseph, 8–9
 - Mycophenolate mofetil (MMF)
 - immunosuppression maintenance, 98–99
 - primate model use, 128
 - Mycophenolate sodium, enteric coated, 98–99
- N**
- Natural killer (NK) cell
 - acute rejection role, 52
 - allogeneic response, 32–33
 - allograft rejection role, 42–43, 245–246
 - depletion, 144
 - Neutrophil, rejection role, 245–246
 - NK cell. *See* Natural killer cell
 - NKG2D, acute rejection role, 52, 58
- O**
- OKT3. *See* Muromonab
 - Opportunistic infection
 - BK virus in kidney transplantation, 349–350
 - epidemiology
 - community exposures, 374
 - donor-derived infections, 372–374
 - exposure categories, 370, 372
 - nosocomial exposures, 374
 - pretransplant infections in recipients, 374
 - immunosuppression net state and risks, 372, 374–375
 - indirect effects of microbiome and immune function, 379
 - lymphocyte depletion complication, 349–350
 - management, 379–380
 - overview, 369–370
 - timeline
 - first month, 376–377
 - overview, 370–371, 375–376
 - six months, 377–378
 - six-to-twelve months, 38–379
 - Organ donation. *See* Ethics, transplantation; *specific transplantations*
 - Owen, Ray, 7
 - OX40 (CD134), costimulatory blockade, 181
- P**
- Pancreas transplantation. *See also* Islet transplantation
 - benefits, 293
 - challenges, 300–301
 - contraindications, 296
 - diabetes, 24, 289–290
 - immunosuppression, 299
 - indications in diabetes, 290–293
 - living donation, 298
 - monitoring of graft, 299–300
 - morbidity, 300
 - organ donation, 297–298
 - outcomes, 293–295, 297
 - surgical technique, 298
 - Pancreas–kidney transplantation (PKT), early versus late, 22–23
 - PCP. *See* *Pneumocystis pneumonia*
 - PD1. *See* Programmed death 1 receptor
 - Pig models, transplantation
 - kidney-induced cardiac allograft induction
 - overview, 327
 - regulatory T-cell studies
 - coculture suppression assays, 328–329
 - host thymectomy, 328
 - major histocompatibility complex-mismatched swine, 329
 - putative intragraft Tregs, 329
 - roles
 - donor antigen load, 327–328
 - donor kidney irradiation, 328
 - donor nephrectomy, 328
 - tolerance induction
 - lymphocyte depletion, 161–162
 - mixed chimerism, 162
 - total body irradiation, 162
 - PKT. *See* Pancreas–kidney transplantation
 - Plasma cell, depletion, 144
 - Plasmacytoid dendritic cell. *See* Dendritic cell
 - Pneumocystis pneumonia* (PCP), prophylaxis, 377
 - Pollock, George, 2
 - Posttransplantation lymphoproliferative disease (PTLD)
 - lymphocyte depletion association, 148, 150
 - risks in tolerance induction, 267
 - viral infection in carcinogenesis after transplantation, 390–391

- Pregnancy, kidney transplantation considerations, 352–353
- Primate models, transplantation
- chimerism induction of allograft tolerance, 133–134, 163–164
 - costimulatory blockade
 - CD154 antibody, 182–183
 - CTLA-4 antibody, 182
 - facial transplantation, 128
 - genetics, 125–126
 - hand transplantation, 128–129
 - heart transplantation, 128
 - immunosuppression regimens
 - adhesion blockade, 132
 - lymphocyte depletion, 132–133
 - standard immunosuppression, 128–130
 - islet transplantation, 127–128
 - kidney transplantation, 126, 322
 - lung transplantation, 128
 - lymphocyte depletion
 - B-cell depletion, 146–147
 - overview, 132–133
 - T-cell depletion
 - alemtuzumab, 146
 - CD3 immunotoxin, 135
 - miscellaneous agents, 146
 - polyclonal antibody preparations, 144–145
 - overview, 125
 - perioperative care, 126
 - skin transplantation, 126–127
 - xenotransplantation, 128
- Programmed death 1 receptor (PD1), costimulatory blockade, 180, 185
- PTLD. *See* Posttransplantation lymphoproliferative disease
- R**
- RAG, knockout mice, 33
- Rapamycin, regulatory T-cell stability effects, 194, 198
- Regenerative medicine (RM)
- hollow organs versus complex modular organs, 414–416
 - Holy Grail concept, 418
 - immunosuppression-free state, 412–414
 - organ waiting lists and needs, 408, 412
 - prospects for study
 - bioreactors, 416–417
 - developmental and evolutionary biology approaches, 416
 - vascularization, 417–418
- Regulatory T cell (Treg)
- allogeneic response, 55
 - autoimmunity role, 192
 - epigenetics, 193–194
 - Foxp3 induction, 192–193
 - functional mechanisms, 195–196
 - kidney-induced cardiac allograft induction studies
 - coculture suppression assays, 328–329
 - host thymectomy, 328
 - major histocompatibility complex-mismatched swine, 329
 - putative intragraft Tregs, 329
 - linked suppression and infectious tolerance, 192
 - memory responses and heterologous immunity, 200
 - positive selection, 193
 - primate models, 329
 - prospects for study, 201, 218–219
 - stability, 194
 - T-cell regulatory cells other than regulatory T cells, 200–201
 - T-cell subset regulation, 198–200
 - therapeutic application
 - adjunct immunosuppression, 213–214
 - advantages, 210–211
 - clinical trials, 217–218
 - dosing, 211–212
 - expansion
 - alloantigen-reactive cells, 215–216
 - characterization of cells, 216–217
 - polyclonal cells, 215
 - induction ex vivo, 216
 - isolation of cells, 214–215
 - off-target effects, 267
 - overview, 194–195, 209–210, 250, 263–265
 - specificity, 212–213
 - tolerance biomarkers, 201
 - tolerogenic microenvironments and immune privilege, 197–198
- Rejection. *See also* Acute rejection; Allogeneic response; Chronic rejection
- adaptive immune response, 43, 243–245
 - facial and hand transplantation, 364
 - innate immune response, 42–43, 245–247
 - mechanisms
 - antibody-mediated rejection, 240–243
 - cell-mediated rejection, 243–247
 - overview, 226–227
 - organ-specific differences, 323
 - types, 41–42
- Rituximab, immunosuppression therapy, 101
- RM. *See* Regenerative medicine
- S**
- Schöne, Georg, 2
- Siplizumab (MEDI-507), immunosuppression therapy, 102
- Sirolimus, immunosuppression maintenance, 99
- Skin transplantation
- acute rejection, 108–109
 - historical perspective, 5–8
 - primate models, 126–127

Sotrastaurin (AEB-071), immunosuppression therapy, 102

Starzl, Tom, 10–11, 13–14, 275–276

T

Tacrolimus

history of use, 13–14

immunosuppression maintenance, 98

TAK-779, chemokine blockade, 45

Tbet, 199

TBI. *See* Total body irradiation

T cell. *See also* Costimulatory blockade; Lymphocyte depletion; Regulatory T cell

acute rejection

activation, 54–56

memory T cells, 56

regulatory T cells, 55

allogeneic response

alloreactivity, 30–32

overview of rejection, 243–245

T cell receptor gene rearrangement, 31

types in transplanted organ recognition, 34–35

complement in cell-mediated graft rejection, 80–81

immunosuppressant drug mechanisms of action, 92–94

ischemia–reperfusion injury facilitation via Toll-like receptor, 84

kidney transplantation rejection, 345

mesenchymal stromal cell suppression of allogeneic T-cell responses in rejection, 230–231

regulatory cells other than regulatory T cells, 200–201

TGF- β . *See* Transforming growth factor- β

Thrombotic microangiopathy (TMA), kidney transplantation, 347

TLR. *See* Toll-like receptor

TMA. *See* Thrombotic microangiopathy

Tofacitinib (CP-690550)

immunosuppression therapy, 102

primate model use, 130

TOL101, immunosuppression therapy, 102–103

Tolerance induction. *See also* Costimulatory blockade; Regulatory T cell

B-cell tolerance induction, 248

clinical significance, 260–261

clinical studies of mixed chimerism, 164–166, 252–263

economic considerations, 267

history of study and definition, 249–260

immunosuppression weaning, 262

kidney-induced cardiac allograft induction. *See* Kidney-induced cardiac allograft induction

mechanism of mixed chimerism induction, 166–169

mesenchymal stromal cell studies

dendritic cell modulation by mesenchymal stromal cells, 229–230

macrophage modulation by mesenchymal stromal cells, 228–229

suppression of allogeneic T-cell responses in rejection, 230–231

mouse model studies

lymphocyte depletion, 158–159

mixed chimerism, 160

organ-specific differences in induction in mice

kidney allografts

alloimmune response, 324–325

plasmacytoid dendritic cell hypothesis, 325

renal tubular epithelial cell hypothesis, 325

liver allografts

alloimmune response, 325–326

hematopoietic stem cell hypothesis, 326

liver sinusoidal endothelial cell hypothesis, 326

plasmacytoid dendritic cell hypothesis, 326

overview, 323–324

pig studies

lymphocyte depletion, 161–162

mixed chimerism, 162

total body irradiation, 162

primate models

central tolerance with mixed chimerism, 115–116, 163–164

peripheral tolerance with costimulatory blockade, 116

prospects for study, 169–170, 268–269

regulatory T-cell therapy. *See* Regulatory T cell

spontaneous tolerance studies, 261–262

Toll-like receptor (TLR)

allogeneic response, 32

allograft rejection role, 85–86

complement pathway cross talk, 86

ischemia–reperfusion injury mediation, 82–84, 87

mesenchymal stromal cell expression, 227

types, ligands, and tissue distribution, 82–83

Total body irradiation (TBI)

immunosuppression in early transplantation, 8–9

pig studies, 162

Transforming growth factor- β (TGF- β), regulatory T-cell function, 196

Treg. *See* Regulatory T cell

U

Ullmann, Emerich, 3

Unger, Ernst, 3

V

Varicella-zoster virus (VZV), opportunistic infection, 372, 377–378

Voclosporin (ISA247), immunosuppression therapy, 102

Voronoy, Yu Yu, 4

VZV. *See* Varicella-zoster virus